NICE publishes survey of evidence of Truvada (emtricitabine/tenofovir disoproxil) in pre-exposure prophylaxis (PrEP) against HIV in adults at a high risk of infection- Gilead Sciences
The National Institute for Health and Care Excellence (NICE) has published a survey of evidence for the use of Truvada (emtricitabine/tenofovir disoproxil) in pre-exposure prophylaxis (PrEP) against HIV in adults at a high risk of infection. NICE considered Truvada effective in reducing HIV acquisition in high risk patients and identified issues that need to be considered in the planning of PrEP services , such as uptake and adherence, sexual behaviour, drug resistance, safety, prioritisation for prophylaxis and cost-effectiveness.
The survey also noted the provision of PrEP may place demands on HIV testing, sexually transmitted infections and hepatitis B screening.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins